Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GNBT Generex -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (51)	1/24/2006 8:58:53 AM
From: Hawkmoon	Respond to of 310

Just a damn shame that the private investors were able to use the market makers to keep the price suppressed to $1.05, rather than $1.25. I was wondering why the price seemed to have a cap at that level. Now we know. But the deed is done and the company has cash to pursue its manufacture and market of its oral diabetes drug, as well as advancing its research of their Avian Flu drug. I think there's some real potential here for major upside over the course of this year. The volume yesterday was absolutely tremendous. The previous volume was 20 million shares. Hawk

To: manny t who wrote (51)	1/24/2006 9:35:57 AM
From: rrufff	Read Replies (3) \| Respond to of 310

Manny - be careful - the filing seems to indicate that the wt. price was .82. I'm in a rush this morning so I haven't had a chance to fully digest it and there are some other formulae later in the filing. In the past, shorts or sellers have often pushed it to the financing price. I may be wrong on this, but check it out for yourself. We make reference to (a) the common stock purchase warrant issued by Generex Biotechnology Corporation (the “ Company ”) to = on September 8, 2005 pursuant to which the Company granted to = the entitlement to purchase up to 609,756 shares of the Company’s common stock at $0.82 per share (the “ Sep Warrant ”), and (b) the common stock purchase warrant issued by the Company to = on December 5, 2005 pursuant to which the Company granted to = the entitlement to purchase up to 1,219,512 shares of the Company’s common stock at $0.82 per share (the “ Dec Warrant ”) (the Sep Warrant and the Dec Warrant are hereinafter together referred to as the “ Warrants ”). The Initial Exercise Date (as that term is defined in both the Sep Warrant and the Dec Warrant) of the Warrants is expressed therein as the 181 st day after the date thereof. The Company hereby confirms that, in consideration of the immediate exercise by = of not less than 100% of both the Sep Warrant and the Dec Warrant and the delivery to the Company of Notices of Exercise in respect thereof on or before the close of business on January 23, 2006, the Company has agreed to abridge the Initial Exercise Date and to honor the aforementioned Notices of Exercise.